NCT00663442

Basic and Clinical Research on Attention Deficit Hyperactivity Disorder (ADHD)

Dose Response Pharmacogenetic Study of ADHD

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 48 (actual)
• Sponsor: University of Illinois at Chicago · Academic / Other
• Sex: All
• Age: 6 Years – 17 Years
• Healthy volunteers: Not accepted

Summary

Children between 6-17 are evaluated for ADHD and and a blood sample is obtained for DNA extraction. If eligible, they participate in a 4 week, double blind, placebo controlled trial with weekly switches. In randomized order, children receive 18, 36, 54 mg. OROS methylphenidate and placebo. Each week, parent report measures, clinical interviews, and safety assessments are conducted. Hypothesis: Efficacy and adverse events will be dose dependent. Dopamine Transporter Genotype will predict response

Conditions

• ADHD

Interventions

Type	Name	Description
DRUG	OROS methylphenidate	18, 36, 54 mg

Timeline

• Start date: 1999-12-01
• Primary completion: 2004-11-01
• Completion: 2004-11-01
• First posted: 2008-04-22
• Last updated: 2008-04-22

Locations

1 site across 1 country: United States